Dr. Garassino on Immunotherapy in EGFR-Mutated Lung Cancer

Marina Chiara Garassino, MD, medical consultant in the Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses immunotherapy for patients with EGFR-mutated lung cancer.

Looking at the subgroup analysis for all randomized clinical trials, there is no clear benefit in EGFR-mutated patients, making it difficult to decide whether to treat with immunotherapy or chemotherapy, explains Garassino.

In the ATLANTIC trial, patients with EGFR-mutated lung cancer were treated with durvalumab (Imfinzi). These patients experienced a benefit with progression-free survival and overall survival, states Garassino.